TrialBlood2023

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.

Jeremy S Abramson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.